Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Pfizer-BioNTech's COVID-19 Shot Moderately Effective Against Omicron In Kids Aged 5 to 15, CDC Study Shows

The Pfizer Inc (NYSE:PFE) - BioNTech SE (NASDAQ:BNTX) vaccine is only moderately effective against the omicron variant when tested in children ages 5 to 15. 

According to a study conducted by the Centers for Disease Control and Prevention (CDC) and Abt Associates, the shot showed 59% efficacy in those ages 12 to 15 and 31% in those ages 5 to 11. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.